Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma.
暂无分享,去创建一个
F. Saad | A. Briganti | S. Shariat | P. Karakiewicz | A. Kapoor | O. de Cobelli | Z. Tian | D. Tilki | A. Tafuri | C. Terrone | M. Cerruto | A. Panunzio | G. Sorce | A. Antonelli | S. Tappero | L. Hohenhorst | M. Piccinelli | F. Chun | Cristina Cano Garcia
[1] L. Mariani,et al. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). , 2022, JAMA oncology.
[2] Wei He,et al. Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma , 2021, BioMed research international.
[3] Wenquan Zhou,et al. Incidence, Clinical Characteristics, and Survival of Collecting Duct Carcinoma of the Kidney: A Population-Based Study , 2021, Frontiers in Oncology.
[4] F. Saad,et al. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. , 2020, European urology focus.
[5] F. Saad,et al. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis , 2020, World Journal of Urology.
[6] H. Miyake,et al. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney , 2019, International Cancer Conference Journal.
[7] M. Colecchia,et al. Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. , 2019, Cancer treatment reviews.
[8] Lorenzo Marconi,et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.
[9] Y. Nagashima,et al. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy , 2018, Medicine.
[10] F. Zhou,et al. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. , 2018, European journal of cancer.
[11] A. Briganti,et al. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. , 2017, European urology focus.
[12] A. Roychoudhury,et al. Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database. , 2017, Urologic oncology.
[13] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[14] J. Hainsworth,et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. , 2016, The Lancet. Oncology.
[15] Y. Allory,et al. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] T. Polascik,et al. Characteristics and outcomes of tumors arising from the distal nephron. , 2012, Urology.
[17] H. Miyake,et al. Metastatic collecting duct carcinoma of the kidney responded to sunitinib , 2010, International Journal of Clinical Oncology.
[18] J. Wright,et al. Effect of collecting duct histology on renal cell cancer outcome. , 2009, The Journal of urology.
[19] S. Culine,et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.
[20] N. Rioux-Leclercq,et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. , 2007, European urology.
[21] S. Naito,et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.